CIL
CILASTATIN
Created: | 2002-02-06 |
Last modified: | 2012-01-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 50 |
Chiral Atom Count | 1 |
Bond Count | 50 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | CILASTATIN |
Systematic Name (OpenEye OEToolkits) | (Z)-7-[(2S)-2-amino-3-hydroxy-3-oxo-propyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropyl]carbonylamino]hept-2-enoic acid |
Formula | C16 H26 N2 O5 S |
Molecular Weight | 358.453 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(N\C(=C/CCCCSCC(C(=O)O)N)C(=O)O)C1CC1(C)C |
SMILES | CACTVS | 3.385 | CC1(C)C[CH]1C(=O)NC(=CCCCCSCC(N)C(O)=O)C(O)=O |
SMILES | OpenEye OEToolkits | 1.7.5 | CC1(CC1C(=O)NC(=CCCCCSCC(C(=O)O)N)C(=O)O)C |
Canonical SMILES | CACTVS | 3.385 | CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSCC(N)C(O)=O)C(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.7.5 | CC1(C[C@@H]1C(=O)N/C(=C\CCCCSCC(C(=O)O)N)/C(=O)O)C |
InChI | InChI | 1.03 | InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11?/m1/s1 |
InChIKey | InChI | 1.03 | DHSUYTOATWAVLW-MSSAFCDDSA-N |
Drug Info: DrugBank
DrugBank ID | DB01597 |
---|---|
Name | Cilastatin |
Groups |
|
Description | Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism. The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co.[L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894] |
Synonyms |
|
Brand Names |
|
Indication | Cilastatin is indicated, in combination with [imipenem] with or without [relebactam], for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.[L7526,L7568] |
Categories |
|
ATC-Code |
|
CAS number | 82009-34-5 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Dipeptidase 1 | MWSGWWLWPLVAVCTADFFRDEAERIMRDSPVIDGHNDLPWQLLDMFNNR... | unknown | inhibitor |
Solute carrier family 22 member 6 | MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR... | unknown | inhibitor |
Solute carrier family 22 member 8 | MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 5280454 |